slide1 l.
Skip this Video
Loading SlideShow in 5 Seconds..
Drug Delivery Company – Two Robust Platform Technologies Rich Product Pipeline – Active Partnering Strategy PowerPoint Presentation
Download Presentation
Drug Delivery Company – Two Robust Platform Technologies Rich Product Pipeline – Active Partnering Strategy

Loading in 2 Seconds...

play fullscreen
1 / 25

Drug Delivery Company – Two Robust Platform Technologies Rich Product Pipeline – Active Partnering Strategy - PowerPoint PPT Presentation

  • Uploaded on

Drug Delivery Company – Two Robust Platform Technologies Rich Product Pipeline – Active Partnering Strategy. Investor Presentation Q1 2011 Safe Harbor Statement.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

Drug Delivery Company – Two Robust Platform Technologies Rich Product Pipeline – Active Partnering Strategy

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Drug Delivery Company – Two Robust Platform Technologies

Rich Product Pipeline – Active Partnering Strategy

Investor Presentation

Q1 2011


Safe Harbor Statement

This presentation contains certain statements that may be forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including statements relating to the product portfolio and pipeline and clinical programs of the combined company, the market opportunities for MuGard™, the sales of, market opportunities for and planned studies of ProLindac™, the market opportunities for Thiarabine and the Cobalamin programs, and the combined company’s goals and objectives. These statements are subject to numerous risks and uncertainties, including but not limited to the risks detailed in Access's Annual Report on Form 10-KSB for the year ended December 31, 2009, and other reports filed by the companies with the Securities and Exchange Commission.

These materials are not an offer to sell securities and are not soliciting an offer to buy securities. 

For Additional Access Pharmaceuticals Information, Go to the Following

Publicly Available Resources:

at AccessPharma

at Access Pharmaceuticals


Corporate Overview & Highlights

  • CobOral and CobaCyte Drug Delivery Platforms – Proprietary drug delivery platforms creates multiple product opportunities; mitigates single product/technology exposure.
  • Late Stage Product Pipeline – Access has received FDA marketing clearance for oral mucositis product MuGard; ProLindac and Thiarabine have completed Phase 2 trials.
  • Partnering Strategy – Access has completed eight partnerships or collaborations in the past 24 months: upfront payments, royalties, research costs, clinical costs.
  • Experienced Team –Experienced chemists, pre-clinical and manufacturing experts, clinical development personnel, and business development and finance personnel.
  • Focus on Shareholder Value – Management and board members are significant shareholders, focused on increasing shareholder value.

Access Pharmaceuticals, Inc.(ACCP.OB) – a drug delivery company with late-stage products for cancer, diabetes and hormone replacement. Several products are based on Access’ proprietary drug delivery platform technologies.


Multiple Platforms Drives Opportunity

Two proprietary, drug-delivery platform technologies enable product development across multiple biotechnology sub-sectors: Cancer, Diabetes, Hormone, Fertility, etc..


MuGard™ - Treating A Significant Health Issue

Significant Medical Issue – Often Unrecognized, Undiagnosed and Undertreated



MuGard™ - Oral Mucositis (OM)

  • >$1 Billion Addressable Market: Target all cancer patients; 1.5 million US cancer patients annually (incidence). Roughly 90% of patients on radiation (43% severe); and 40% of patients receiving chemotherapy.
  • MuGard Stands Alone:Only oral mucositis product that instructs pre-treatment; Safe to swallow on label.
  • US Commercial Launch: US manufacturing completed – launch activities underway.
  • Multiple Marketing Partners: Partners signed for EU, Switzerland, Norway, Iceland, China, Korea.
  • Royalties: 20%, scaling to 25%

Large Unmet Medical Need – Commercially Launching in US, Europe and Far East


MuGard’s Industry Leading Label

Indications: indicated for the management of pain and relief of pain…

Directions for use: Gargle and spit out.

Indications: dryness or dry mouth associated with various conditions

Directions for use: Swish and spit out.

Indications: “Magic mouthwash" prepared by pharmacists and used to treat mouth sores (oral mucositis)

Directions for use: Gargle and spit out

Indications: MuGard is indicated for the management of oral mucositis/ stomatitis

Directions for use:

… rinse may be expelled or swallowed … safe to swallow …

…recommended that patients purchase MuGard™prior to the commencement of cancer therapy ..

MuGard is recommended for preventative use

MuGard can be swallowed to coat lesions in throat



MuGard: US Distribution Strategy

  • Oncology Network Sampling Program
        • MuGard Centers-of Excellence
        • Broad-scale sampling program to top oncology networks to educate and promote the benefit MuGard provides patients
  • BioScrip (Nasdaq: BIOS) Specialty Distribution Partner
        • Nationwide distribution platform with extensive physician network
        • Live “stand-alone” retail pharmacies in over 30 top metro areas
        • 75,000 square-foot mail distribution facility in Columbus, Ohio
        • Various order and delivery options for patient
        • Judicator of claims – handles insurance claims process
  • iMedicor and Direct Medical Solutions
        • Non-personal online marketing capability
        • Direct Medical Solutions - direct sales reps
        • Supports other distribution channels


MuGard: US Commercial Launch Activities

  • Achieved scale-up manufacturing of MuGard (Accupac) – product manufactured and shipped to specialty distributor
  • Key opinion leader collaboration (Dr. Stephen Sonis) – Oral Mucositis expert
  • Launch sampling program – targeting large oncology networks to build awareness and clinical experience with MuGard
  • Work with reimbursement consultants – filed reimbursement coding application and discussions are ongoing with major third-party payers
  • Additional MuGard clinical data, ongoing and at MASCC
  • Secure Additional Distribution Channels – Ongoing
  • Long-term Stability for full commercial availability
  • Additional MuGard partnerships

ACCP Remains On-track for Full-Scale North American MuGard Launch


Cobalamin– oral drug delivery platform

to enhance absorption of large molecules






CobOral / CobaCyte Drug Delivery Platforms

Using The Body’s Own Vitamin B-12 Absorption System

To Enable and Enhance Delivery of Drugs

The “Trojan Horse” Delivery Vehicle

The nanoparticle coated

with Cobalamin (red)

binds to intrinsic factor (1),

which in turn binds to its

cell surface receptor (2).

The nanoparticle is

transported across the

cell (3), crosses the gut

wall and enters the

bloodstream (4).

Nanopolymer “payload” can be

Insulin, growth hormone, EPO, etc.


CobOral Oral Insulin Program

Cobalamin Enhanced Nanopolymers – Enabling Oral Insulin

Multiple CobOral Formulation Agreements In Place

Clinically Relevant Glucose Lowering

Effect in Diabetic Rat Model


  • CobOral technology makes “active drug” look like Vitamin B-12; achieved significant levels of oral bioavailability with insulin and HGH
  • Studies conducted on numerous products including Insulin, LHRH, EPO, Interferon, G-CSF
  • Seeking co-development partner in diabetes field
  • Potential for use in wide variety of disease states where vitamin intake is up regulated, including cancer, rheumatoid arthritis, Crohn’s, autoimmune disorders

Significant Oral Bioavailability

  • CobOral Oral Insulin– Access has achieved unprecedented levels of oral bioavailability of insulin in two animal models ( >80% of that achieved by injection).
  • Multiple Ongoing Collaborations– Oral insulin provided to collaborators that have confirmed high levels of oral bioavailability; new collaborations ongoing
  • CobOral Human Growth Hormone– Demonstrated high oral bioavailability and a 25% improvement in weight gain in standard animal model
  • Multiple Applications– Ongoing discussions with multiple potential partners looking at exploiting CobOral/CobaCyte oral drug delivery for insulin, HGH, fertility drugs, proteins, etc.
  • Patent Life-cycle Management Tool –protect patent (IP) position through cobalamin formulation of existing drugs, resulting in new IP
  • sRNAi – Adaptation of Cobalamin system to provide delivery vector for sRNAi therapeutics being evaluated; partnering and collaboration discussions ongoing

Multiple Collaborations Driving Enhanced Data Set;

Planning Initiation of Phase 1 Human Trial in Cobalamin Oral Insulin



  • ProLindacTM – Access designed a second generation DACH platinum using our proprietary nano-polymer expertise.
  • Eloxatin®
    • FDA approved (2001) for front-line metastatic colorectal cancer
    • 2008 $2.5+ billion projected sales globally
    • Significant neurotoxicity
  • Partnering On-going– Partnered with Aosaikang Med Group (ASK) in China and JCOM in Korea. Partners paid upfront, committed to run 3 clinical trials that ACCP controls, and royalties.

Positioning ProLindac™ as a Replacement for Sanofi-Aventis’ Eloxatin

Represents a $3+ Billion Market Opportunity

DACH Platinum (same active in Eloxatin) is inactive while attached to polymer background

Chelator releases platinum compound in low pH environment; e.g. tumor


ProLindac™ Phase II Trial – Relapsed Ovarian

  • Monotherapy in relapsed, platinum-sensitive patients
    • 36 patients enrolled in six centers in France; final follow-up ongoing
    • Heavily treated patients (at least 3, up to 7, previous regimens)
    • Exploring two dosing schedules (once/two weeks and once/three weeks)
  • Safety – ProLindac Exhibited Very Benign Safety Profile
    • Patients tolerating drug well through multiple cycles (up to 10 or more)
    • No Eloxatin-like neurotox; no nephrotox; no hematotoxicity; no worse emesis
  • Efficacy and Activity – ProLindac “Outperforms” Current Best Care
    • At highest doses, 66.7% ProLindac patients responded; Activity levels superior to oxali or carbo in monotherapy in similar but healthier patient populations (approx 20%)
  • Next Steps
    • First combination trial launched: ProLindac plus taxol in recurrent ovarian; partners planning additional combination trials (ProLindac plus Lilly’s Gemzar in liver and pancreatic cancer)
    • Partnering discussions ongoing

Final Study Results – Safe and Active DACH Platinum Drug


Thiarabine – Phase II cancer drug

for Leukemias and Lymphomas


Thiarabine – A Novel Nucleoside Analogue

  • New Nucleoside Analogue – Same class as other clinically successful FDA approved nucleoside analogues such as fludarabine and cladrabine; Clofarabine was approved after a single 44 patient study.
  • Significant Data/Information Known – Drug was well tolerated and active in two previously conducted Phase II clinical trials in advanced solid tumors. Significant clinical pharmacology and dose scheduling information known.
  • MD Anderson Cancer Center – Principal investigator is Hagop Kantarjian, M.D., Head of Leukemia Dept. at MD Anderson(same team of experts that have successfully led to approved nucleoside analogues in leukemias and lymphomas).
  • Clinical Plan – Pre-clinical and clinical studies indicate strong potential in leukaemia or lymphoma. Based upon clinical data, ACCP is finalizing trial designs and protocols in AML, ALL, and B-cell lymphomas.

Significant Clinical Data Available – Initiated Phase I/II study

at MD Anderson Cancer Center


Active Partnering Strategy For Drug Programs

  • SpePharm, B.V. –MuGard marketing partner in European Union; rolling launch of MuGard ongoing in UK, Germany, Italy, Nordic countries, Greece; anticipated launches in France, Benelux, Spain and throughout EU continues.
  • Aosaikang Medicinal Group (ASK)–Rights to ProLindac in greater China; provides second source manufacturing; obligated to pay for two controlled combination studies
  • JCOM Ltd – Rights to ProLindac in Korea; obligated to pay for one pivotal controlled combination study.
  • JCOM Ltd–Rights to MuGard in Korea; secured MuGard marketing approval and preparing commercial launch in 2010
  • RHEI Pharma: – Rights to MuGard in greater China; securing regulatory approval, and seeking source of supply; preparing for commercial launch
  • US Large Pharma – Multiple sponsored formulation agreements evaluating cobalamin oral drug delivery platform (various large molecules, insulin, GLP, HGH)
  • US and European Biotechnology Company –Material transfer agreement and collaboration agreement

Active Business Development Effort; Securing Partnerships and

Collaborations to Enhance Value and Share Costs


Experienced Management Team

  • Jeffrey B. Davis, Chief Executive OfficerPresident, SCO Financial Group LLC; Senior Vice President and Chief Financial Officer of a healthcare technology company; Vice President, Corporate Finance, at Deutsche Morgan Grenfell; Senior marketing and product management positions at AT&T Bell Laboratories; Marketing and Product Manager at Philips Medical Systems North America. MBA, The Wharton School, University of Pennsylvania; BS Biomedical Engineering, Boston University.
  • Esteban Cvitkovic, M.D., Vice Chairman, Senior Director, Clinical Oncology R&DDr. Cvitkovic is a board-certified oncologist with more than 30 years experience in oncology therapeutics, including clinical research, clinical pharmacology, design of single-agent and combination regimens, and optimization of clinical efficacy. Dr. Cvitkovic played a fundamental role in the registration strategy and post-registration development of cisplatin and oxaliplatin. Dr. Cvitkovic has held staff and academic appointments at Memorial Sloan Kettering Cancer Center (NY), Columbia Presbyterian (NY), Hospital St. Louis (Paris), Instituto Mario Negri (Milan) and InstitutGustaveRoussy (Villejuif).
  • Frank Jacobucci, Vice President Sales & Marketing

Mr. Jacobucci has over 20 years experience in sales management, including senior sales executive positions at oncology focused companies including MGI Pharma, Genetics Institute, Wyeth Oncology, Aventis, Precision Therapeutics and CRC Oncology Services.

  • David P. Nowotnik, Ph.D., Senior Vice President Research and DevelopmentSenior Director, Product Development, Guilford Pharmaceuticals, Inc.; Group Leader, Bristol-Myers Squibb. Section Leader, Amersham International. Research Chemist, Tate and Lyle and Aspro-Nicholas. PhD, Organic Chemistry, University of London.
  • Stephen B. Thompson, Vice President and CFOController and Administration Manager, API; Controller, Robert E. Woolley, Inc., a hotel real estate company; Controller, OKC Limited Partnership, an oil and gas company. Accounting and finance, Santa Fe International Corporation.
  • Phillip Wise, Vice President Business Development and StrategyVP, Commercial and Business Development and Chief Financial Officer, Enhance Pharmaceuticals; VP, Commercial and Business Development, Ardent Pharmaceuticals; Director of Managed Care Marketing & Director of New Product Planning, GlaxoWellcome; MBA, University of Virginia; BS, Industrial and Systems Engineering, Georgia Institute of Technology.

Board of Directors

Strong Board of Directors with Relevant Experience

  • Steven H. Rouhandeh, ChairmanSteve Rouhandeh is a Chief Investment Officer of SCO Capital Partners, L.P., a New York based life sciences fund.  Steve also is a founder of SCO Financial Group LLC, a highly successful value-oriented healthcare group with 11-year track record in sector (advisory, research, banking and investing). Steve possesses a diverse background in financial services that includes experience in asset management, corporate finance, investment banking and law.
  • Esteban Cvitkovic, M.D., Vice Chairman – see Management
  • Mark Ahn, Ph.D.Dr. Ahn is currently Professor and Chair of the Science & Technology Entrepreneurship Faculties of Commerce & Administration and Science at the Victoria University of Wellington, in Wellington, New Zealand. Previously, Dr. Ahn was President and CEO of Hana Biosciences, Inc., and earlier, Vice President Hematology at Genentech, Inc. where he was responsible for Rituxan. Prior to that, Dr. Ahn held senior positions at Bristol-Myers Squibb, Amgen and FMC Corporation.
  • Mark AlvinoMark Alvino is a Managing Director at Griffin Securities, a leading provider of corporate finance advisory and brokerage services to the life sciences industry. Prior to that, Mark was a Managing Director for SCO Securities, and additionally held several senior management positions within the investment banking and investor relations industries
  • Stephen B. Howell, M.D.Dr. Howell is Professor of Medicine, University of California at San Diego, and has extensive experience in platinum therapeutics. Dr. Howell is also a Director of Clinical Investigation and Development Therapeutics Program, UCSD Cancer Center, and has previously received the Milken Foundation prize for contributions to cancer chemotherapy.
  • Jeffrey B. Davis, Chief Executive Officer – see Management



Financial Overview

  • Ticker: ACCP (OTCBB)
  • Capital Structure

Common shares outstanding 19.2 million shares

Common under preferred shares 11.7 million shares

Total common shares 30.9 million shares

  • Debt: $5.5 million note due end 2011, convertible at $27.50 per share.
  • Cash Burn: Roughly $4 million annually. With current cash on balance sheet and expected upfront and milestone payments, Access has sufficient cash into 2012.
  • High Quality Institutional Investors: Includes SCO Capital Partners, Oracle Partners, CSFB, Schroeder’s Bank

Milestones / News Flow – 2011 and forward

Significant News Flow Anticipated in 2011 and 2012

  • Global roll-out of MuGard for oral mucositis
  • Initiate dose-escalating trial for Thiarabine
  • Initiate ProLindac combination Phase 2 trial
  • Multiple CobaOral / CobaCyte formulation agreements
  • Far East launches of MuGard
  • Additional MuGard co-promotion / partnerships
  • CobOral / CobaCyte collaborations and data
  • ProLindac and Thiarabine clinical data
  • Seek global or regional partnerships for ProLindac, Thiarabine, and Cobalamin programs



Conclusions – Investment Highlights

      • CobaOral / CobaCyte Drug Delivery Platforms – multiple long term opportunities (oral insulin, oral HGH, fertility drugs, etc.); multiple collaborations ongoing; launch Phase I human trial in oral insulin
  • Late Stage Oncology Pipeline: Proprietary technology has created portfolio of new products for large markets
        • One FDA-Approved product, MuGard – North American launch; intro in Europe underway; Asia next; >$1 billion opportunity
        • One Phase 2/3-ready cancer drug, ProLindac – New form of proven drug, takes direct aim at Sanofi’s $2.5 billion Eloxatin franchise
        • One Phase 2-ready cancer drug, Thiarabine – superior version of clinically and commercially successful nucleoside analogue
  • Commercial Strategy: Multi-local development and marketing partners to shift risk and share costs, while retaining very attractive revenue/royalty rights.
  • Value Visibility: Seek “re-listing” on national exchange; actively present company to the investment community.

ACCP – An Undervalued Investment Opportunity